Brendan Strong

SVP, Investor Relations & Corporate Communications at Karyopharm Therapeutics

No bio yet


Org chart

No direct reports

Teams

This person is not in any teams


Offices

This person is not in any offices


Karyopharm Therapeutics

13 followers

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an innovation-driven pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1).


Industries

Employees

201-500

Links